Rebimastat (BMS-275291, D2163) is a potent, broad spectrum matrix metalloproteinase (MMPs) inhibitor with potential antineoplastic activity, shows nM potency against MMP-1/2/7/9/14.BMS-275291 inhibits tumor growth in a B16BL6 model of experimental metastasis, BMS-275291 treatment results in a dose-dependent reduction in the number of lung metastases.BMS-275291 also inhibits angiogenesis in a murine angiogenesis model with a dose-dependent inhibition of endothelial cell migration.Rebimastat (BMS-275291) induces extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.

SC-78080 (SD-2590) is a potent, selective inhibitor of MMP2/9/13 with IC50 of <0.1/0.18/<0.1 nM, respectively.SC-78080 shows weaken inhibitory effect on MMP3/8, and no inhibition on MMP1/7.

NNGH is a stromelysin-1 (MMP-3) inhibitor. MMP-3 is both a direct transcriptional target and a necessary contributor of the Wnt/β-catenin signaling pathway. Matrix metalloproteinases (MMPs) play a well-defined role in later stages of tumor progression.

ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP). Inhibition of matrix metalloproteinases (MMPs) is expected to suppress atherosclerotic neointimal proliferation and thus limits atheromatous plaque progression. ONO-4817 suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit.

JG26 is an ADAM17 inhibitor, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM for ADAM8, ADAM17, ADAM10 and MMP-12, respectively.

TP0556351 is a potent and selective matrix metalloproteinase-2 (MMP2) inhibitor with an IC50 value of 0.2 nM. TP0556351 reduces the amount of collagen in the lungs of a Bleomycin-induced pulmonary fibrosis mouse model. TP0556351 can be used for researching idiopathic pulmonary fibrosis (IPF).

(Rac)-Tanomastat ((Rac)-BAY 12-9566) is the racemate of Tanomastat. Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models.

PPNDS tetrasodium is a selective and competitive meprin β inhibitor (IC50: 80 nM, Ki: 8 nM), and also inhibits ADAM10 (IC50: 1.2 μM). PPNDS tetrasodium is also a P2X1 receptor antagonist. PPNDS is an agonist for the ATP receptor of Paramecium. PPNDS tetrasodium potently inhibits polymerases from viruses. PPNDS tetrasodium can be used in the research of infection and cancers.

TP0597850 is a selective inhibitor of MMP2 (IC50=0.22 nM). TP0597850 has a long MMP2 dissociation half-life (t1/2=265 min).

cis-ACCP is an orally active antimetastatic matrix metalloproteinase-2 (MMP-2) selective inhibitor. cis-ACCP can inhibit MMP-2 and MMP-9 with IC50 values of 4 μM and 20 μM, respectively. cis-ACCP can be used for the research of a variety of chronic diseases.

INCB3619 is a selective and orally active ADAM inhibitor with IC50 of 22 nM and 14 nM for ADAM10 and ADAM17, respectively. INCB3619 has anti-tumor activity.

ADAM9i is a specific small molecule inhibitor of ADAM9 protein with binding KD of 5.9 uM and enzyme IC50 of 5.2 uM, promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy.

AZD1236 is a potent, selective MMP-9 and MMP-12 inhibitor with IC50 of 4.5 and 6.1 nM respectively, >10-fold selectivity to MMP-2 and MMP-13 and >350-fold selectivity to other MMPs.

BAY-9835 is the first orally bioavailable ADAMTS7 inhibitor with IC50 of 6 nM, which is selective against a range of off-targets and metalloproteases except for ADAMTS12.

CID 3117694 is a selective, non-competitive inhibitor of ADAM10 with IC50 of 1.1 uM, does not inhibit ADAM17.

IPR-179 (ACT-03) is a potent, BBB-permeable, selective gelatinase (MMP2 and MMP9) inhibitor with IC50 of 656 nM and 310 nM, respectively.

JTP-96193 (JTP96193) is a potent, selective TNF-α converting enzyme (TACE/ADAM17) inhibitor with IC50 of 5.4 nM, >1800-fold selectivity against ADAM10.

MMP118 is a potent, selective and orally bioavailable matrix metalloproteinase-12 (MMP-12) inhibitor with IC50 of 1.0 nM (hMMP-12), 1980- and 154-fold selectivity over MMP-13 and MMP-8 respectively.

MMP408 (MMP 408) is a potent, selective matrix metalloprotease 12 (MMP-12) inhibitor with IC50 of 2.0 nM (human MMP-12), 60-fold selectivity over MMP-13.

TAPI-0 is a potent, selective inhibitor of TNFalpha converting enzyme (TACE, ADAM7) with IC50 of 100 nM.

TP0628103 is a highly potent, selective matrix metalloproteinase-7 (MMP-7) inhibitor with IC50 of 0.17 nM and 4.1 nM for human and mouse MMP-7, respectively.